Codex DNA Reports Fourth Quarter and Full Year 2021 Financial Results and Provides 2022 GuidanceGlobeNewsWire • 03/22/22
Codex DNA Announces Registration and Webcast Information for Upcoming R&D Webinar on March 29, 2022GlobeNewsWire • 03/03/22
Codex DNA to Report Fourth Quarter 2021 Financial Results on Tuesday, March 22, 2022GlobeNewsWire • 03/02/22
Codex DNA to Participate in the SVB Leerink 11th Annual Global Healthcare ConferenceGlobeNewsWire • 02/09/22
Codex DNA Showcases Potential of Groundbreaking SOLA Enzymatic DNA Synthesis Approach to Accelerate Development of Vaccines and TherapeuticsGlobeNewsWire • 01/18/22
Codex DNA Signs Early Access Collaboration and Licensing Agreement with Pfizer to Further Develop Codex DNA's Novel Enzymatic DNA Synthesis Technology for Pfizer's use in its Research and Development of mRNA-based Vaccines and BiotherapiesGlobeNewsWire • 01/10/22
Pfizer's Codex DNA Deal Hints At Lucrative Pivot To mRNA - Keep An Eye On This SpaceSeeking Alpha • 01/06/22
Codex DNA Expands Catalog of COVID-19 Tools with Release of Full-Length Synthetic Genome for SARS-CoV-2 Omicron VariantGlobeNewsWire • 12/23/21
Codex DNA Announces Commercial Availability of Automated mRNA Synthesis Kit with Integrated Capping Technology for BioXp™ SystemGlobeNewsWire • 11/29/21
Codex DNA, Inc. (DNAY) CEO Todd Nelson on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/14/21
Codex DNA to Report Third Quarter 2021 Financial Results on Tuesday, November 9, 2021GlobeNewsWire • 11/02/21
Codex: Synthetic DNA/mRNA Instrument Developer Holds Impressive Upside In 2021Seeking Alpha • 09/24/21
Codex DNA, Inc. (DNAY) CEO Todd Nelson on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/10/21
Codex DNA to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021GlobeNewsWire • 08/03/21
Codex DNA Shares Move Higher On Licensing, Supply Deal With TriLink For mRNA Capping TechBenzinga • 07/21/21